The Company is maintaining its previously issued 2024 revenue guidance of $79-81M and confirms its view of expected adjusted EBITDA profitability in the first half of 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDXH:
- Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
- Is MDXH a Buy, Before Earnings?
- MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
- MDxHealth director Jan Pensaert resigns
- MDxHealth Sees FY23 revenue $70.2M, consensus $69.15M